Andexanet alfa Reduces Hematoma Expansion Following Controlled Cortical Impact in Mice Pretreated with Rivaroxaban
Our experimental data suggests that the use of andexanet alfa improves functional outcomes by reduction of factor Xa inhibitor-associated hematoma expansion in the subacute phase following TBI.
Authors
- Ferdinand O. Bohmann (ORCID: https://orcid.org/0000-0001-6439-0667)
- Franziska Lieschke (ORCID: https://orcid.org/0000-0002-5426-9174)
- Sarah Gelhard
- Michelle Rosenthal-Rueckeis
- Christian Grefkes
Institutions
- Goethe University Frankfurt (DE)
- University Hospital Frankfurt (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Neurocritical Care
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1007/s12028-026-02463-w
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca